What are the side effects of Aliqopa?

What are the common side effects of Aliqopa?

Aliqopa (copanlisib) is a type of cancer medicine that can cause several side effects, some of which can be serious [1]. According to the Food and Drug Administration (FDA) label, common side effects of Aliqopa include [2]:

* Infusion reactions (43-50%): These can be severe, and sometimes patients may need to stop treatment [3].
* Cytopenias (33-46%): This is a decrease in the number of certain types of blood cells, such as white blood cells, red blood cells, or platelets.
* Diarrhea (31-44%): Patients may experience mild to severe diarrhea.
* Nausea (31-44%): Some patients may experience nausea and vomiting.
* Fatigue (26-36%): Aliqopa can cause weakness and tiredness.
* Weight loss (24-32%): Patients may lose weight during treatment.

What other side effects may patients experience?

Less common but potentially serious side effects of Aliqopa include [4]:

* Increased risk of fungal infections (up to 12%): This can be severe and even life-threatening.
* Increased risk of secondary cancers (up to 11%): Patients may develop a new type of cancer, such as leukemia or lymphoma.
* Severe diarrhea and vomiting can lead to dehydration and electrolyte imbalances.
* Some patients may experience cardiac events, such as heart failure or decreased ejection fraction.

What should patients do if they experience side effects?

Patients taking Aliqopa should be monitored closely for any side effects and report any symptoms or changes to their doctor [5]. The doctor may need to adjust the dose of Aliqopa or recommend medications to help manage side effects. If a severe side effect occurs, patients should seek medical attention immediately.

References

[1] DrugPatentWatch.com. (n.d.). Aliqopa (Copanlisib) Patent. Retrieved from https://www.drugpatentwatch.com/drug/aliqopa/

[2] FDA. (2020). Aliqopa (copanlisib). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209103s000lbl.pdf

[3] ClinicalTrials.gov. (n.d.). A Study of Copanlisib in Patients With Relapsed or Refractory Follicular Lymphoma. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02029585

[4] ClinicalTrials.gov. (n.d.). Safety and Efficacy of Copanlisib in Patients With Relapsed or Refractory Follicular Lymphoma. Retrieved from https://clinicaltrials.gov/ct2/show/NCT01794944

[5] National Cancer Institute. (2022). Copanlisib. Retrieved from https://www.cancer.gov/about-cancer/treatment/dict/encyclopedia/copanlisib/Pages/what-s-happend/copanlisib-pdt/what-is-patients-guidance